Regenxbio reports positive interim data from Phase 1/2 microdystrophin gene therapy trial

Regenxbio shared positive data from the AFFINITY DUCHENNE trial of RGX-202.  In addition to robust microdystrophin expression, Regenxbio reported functional benefits at 9 and 12 months after treatment for all of the first 5 participants receiving the pivotal dose (2E14 GC/kg), aged 6-12 years at dosing.  You can learn more here and during a webinar [REGISTER HERE], CureDuchenne is hosting with Regenxbio on Wednesday, June 11^th at 1 pm ET. 

Read the Community Letter Below: